Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Sarepta Therapeutics (NQ: SRPT ) 125.05 +0.43 (+0.35%) Streaming Delayed Price Updated: 11:59 AM EDT, Sep 26, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Headline News about Sarepta Therapeutics < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > 10 Health Care Stocks With Whale Alerts In Today's Session September 18, 2024 Via Benzinga These 2 Biotech Stocks Are Set to Soar September 13, 2024 Innovative drugmakers developing treatments for conditions with high unmet needs can produce lucrative wins. Via The Motley Fool Unveiling 26 Analyst Insights On Sarepta Therapeutics September 06, 2024 Via Benzinga Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy September 03, 2024 Dyne Therapeutics revealed new clinical data from its Phase 1/2 DELIVER trial of DYNE-251 for Duchenne muscular dystrophy, showing significant increases in dystrophin expression and meaningful... Via Benzinga Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Its C-Suite Just Fled The Building September 03, 2024 The company is hoping to rival Sarepa's Exondys 51. But three executives just departed on what is calls "unprecedented" test results. Via Investor's Business Daily How Is The Market Feeling About Sarepta Therapeutics? August 16, 2024 Via Benzinga A Closer Look at 28 Analyst Recommendations For Sarepta Therapeutics August 15, 2024 Via Benzinga $100 Invested In This Stock 10 Years Ago Would Be Worth $600 Today August 12, 2024 Via Benzinga Smart Money Is Betting Big In SRPT Options August 08, 2024 Via Benzinga 2 Biotech Stocks to Buy Hand Over Fist in August August 12, 2024 Both of these biotechs are highly innovative companies. Via The Motley Fool Warner Bros, Airbnb And Monster Beverage Are Among Top 10 Large Cap Losers Last Week (Aug 4-Aug 10): Are The Others In Your Portfolio? August 11, 2024 These 10 stocks had the biggest drop last week, with McKesson Corporation, BIO-TECHNE Corp, and Warner Bros. Discovery, Inc. being the worst performers. Via Benzinga How Avidity Biosciences Just Dropped The Hammer On Sarepta Therapeutics August 09, 2024 The company is coming up fast with a platform that could take on several of Sarepta's approved treatments. Via Investor's Business Daily McKesson Reports Weak Sales, Joins JFrog, Fastly, Warner Bros. Discovery And Other Big Stocks Moving Lower In Thursday's Pre-Market Session August 08, 2024 Via Benzinga NASDAQ:SRPT may be ready to breakout. August 02, 2024 NASDAQ:SRPT may be ready to breakout. Via Chartmill 26 Analysts Have This To Say About Sarepta Therapeutics July 29, 2024 Via Benzinga Here's How Much $1000 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today July 18, 2024 Via Benzinga Here's How Much $100 Invested In Sarepta Therapeutics 10 Years Ago Would Be Worth Today July 04, 2024 Via Benzinga 7 Biotech Stocks to Buy for Their Game-Changing Potential August 08, 2024 Although the market may be reeling from the recent fallout, the red ink presents a viable opportunity in these biotech stocks. Via InvestorPlace Sarepta Therapeutics (SRPT) Q2 2024 Earnings Call Transcript August 08, 2024 SRPT earnings call for the period ending June 30, 2024. Via The Motley Fool Topics Earnings Exposures Financial SRPT Stock Earnings: Sarepta Therapeutics Beats EPS, Misses Revenue for Q2 2024 August 07, 2024 SRPT stock results show that Sarepta Therapeutics beat analyst estimates for earnings per share but missed on revenue for the second quarter of 2024. Via InvestorPlace 3 Genomics Stocks That May Transform Personalized Medicine August 06, 2024 These are three of the best genomics stocks to buy for a lucrative entry into a specialized section of the biotech industry. Via InvestorPlace SAVA Stock Plunges as Cassava Sciences CEO Steps Down. What to Know. July 17, 2024 The CEO of Cassava Sciences is stepping down, effective immediately. Here's what this means for troubled SAVA stock. Via InvestorPlace Jim Cramer Says Don't Sell Match Group: 'You've Just Got A Very, Very Smart Investor In There' July 17, 2024 Jim Cramer doesn't favor Fortinet, but owns Palo Alto Networks for charity. Air Products not doing well due to better run company Linde. Via Benzinga Expert Outlook: Sarepta Therapeutics Through The Eyes Of 25 Analysts July 01, 2024 Via Benzinga Looking At Sarepta Therapeutics's Recent Unusual Options Activity June 26, 2024 Via Benzinga After a Big Win, Is Sarepta Therapeutics Stock a Buy? July 06, 2024 One key issue remains unresolved, and it could be a significant one. Via The Motley Fool Has Sarepta Therapeutics Become a No-Brainer Stock Buy After This Recent FDA News? July 04, 2024 The label expansion paves the way for much more revenue growth for Sarepta in the years ahead. Via The Motley Fool Exposures Product Safety 1 Soaring Growth Stock to Buy and Hold for 10 Years July 03, 2024 Let's look beyond the biotech's performance this year. Via The Motley Fool Is Pfizer's Pain Sarepta Therapeutics' Gain? Don't Bet on It. June 26, 2024 One company's negative results can increase scrutiny of another's work. Via The Motley Fool Here's How Much You Would Have Made Owning Sarepta Therapeutics Stock In The Last 10 Years June 24, 2024 Via Benzinga < Previous 1 2 3 4 5 6 7 8 9 ... 13 14 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.